Loading
What changed between revision 1 and revision 2, compared over the article's markdown source with its frontmatter — so a change to status, evidence or reversibility shows up as the edit it is.
Older · revision 1
Import· initial corpus import, not an edit
Initial import of content/methuselah-foundation.md — the filesystem corpus, unchanged. Not an edit.
10.5 kB
Revision 1
Revision 2
lines 7–14 → 7–146 unchanged lines not shown
categories: ["organizations", "longevity"]categories: ["organizations", "longevity"]tags: ["aging", "prizes", "nonprofit", "tissue engineering", "organ preservation", "research funding"]tags: ["aging", "prizes", "nonprofit", "tissue engineering", "organ preservation", "research funding"]summary: "A Virginia nonprofit founded in the early 2000s that used prize competitions to seed research on life extension, regenerative medicine and organ engineering."summary: "A Virginia nonprofit founded in the early 2000s that used prize competitions to seed research on life extension, regenerative medicine and organ engineering."updated: "2026-07-27"updated: "2026-08-23"issues: ["The Thiel donation and the New Organ Liver Prize sums are stated without a source."]issues: ["The New Organ Liver Prize sum is given only as an order of magnitude and carries no source."]------ ```infobox```infoboxlines 51–59 → 51–5936 unchanged lines not shown
From 2014 the foundation extended the prize model to regenerative medicine under the New Organ banner, motivated by the [[organ-shortage]] arithmetic: transplant waiting lists are limited by donor supply, and no amount of surgical improvement changes that.From 2014 the foundation extended the prize model to regenerative medicine under the New Organ banner, motivated by the [[organ-shortage]] arithmetic: transplant waiting lists are limited by donor supply, and no amount of surgical improvement changes that. The New Organ Liver Prize offered a seven-figure award for a bioengineered liver that could sustain a large animal for a defined period. It went unclaimed, which is an accurate reflection of where [[organ-bioprinting]] and [[tissue-engineering]] stand: vascularization at scale remains unsolved, and no whole solid organ has been grown and successfully transplanted.The New Organ Liver Prize offered a seven-figure award for a bioengineered liver that could sustain a large animal for a defined period. No winner has been announced, which is an accurate reflection of where [[organ-bioprinting]] and [[tissue-engineering]] stand: vascularization at scale remains unsolved, and no whole solid organ has been grown and successfully transplanted. The foundation also partnered with NASA on the Vascular Tissue Challenge, a competition to produce thick, metabolically functional vascularized human tissue that survives in the laboratory for a month. That prize was awarded in 2021 to a team from Wake Forest, and it is the clearest demonstration that a well-specified target in this area can be met.The foundation also partnered with NASA on the Vascular Tissue Challenge, run through its New Organ Alliance under NASA's Centennial Challenges programme: a $500,000 purse for teams producing vascularized human tissue more than a centimetre thick that keeps at least 85 percent of its cells alive through a 30-day trial. In June 2021 two teams from the Wake Forest Institute for Regenerative Medicine took first and second place with bioprinted liver tissue,[^nasa2021] and the result is the clearest demonstration that a well-specified target in this area can be met. A related programme, the Organ Preservation Alliance, worked on extending the viability window for donated organs — the problem that [[cryonics|vitrification]] and normothermic perfusion research addresses, and one where progress has real near-term clinical value regardless of what one believes about life extension.A related programme, the Organ Preservation Alliance, worked on extending the viability window for donated organs — the problem that [[cryonics|vitrification]] and normothermic perfusion research addresses, and one where progress has real near-term clinical value regardless of what one believes about life extension. lines 61–67 → 61–671 unchanged line not shown
[[ { "year": "2003", "title": "Mprize launched", "text": "Two prizes are announced: one for the longest-lived mouse, one for the greatest late-onset extension, the latter designed to reward rejuvenation rather than slowed development." }, { "year": "2003", "title": "Mprize launched", "text": "Two prizes are announced: one for the longest-lived mouse, one for the greatest late-onset extension, the latter designed to reward rejuvenation rather than slowed development." }, { "year": "2003–2004", "title": "First winners", "text": "Andrzej Bartke wins the longevity category with a dwarf mouse living beyond 1,800 days; Stephen Spindler wins the rejuvenation category with late-onset caloric restriction." }, { "year": "2003–2004", "title": "First winners", "text": "Andrzej Bartke wins the longevity category with a dwarf mouse living beyond 1,800 days; Stephen Spindler wins the rejuvenation category with late-onset caloric restriction." }, { "year": "2006", "title": "Major donation", "text": "Peter Thiel commits several million dollars, one of the first large private gifts to life-extension research and a signal to other technology donors." }, { "year": "2006", "title": "Major donation", "text": "Peter Thiel pledges $3.5 million — direct funding plus a matching challenge — one of the first large private gifts to life-extension research and a signal to other technology donors." }, { "year": "2009", "title": "SENS spun out", "text": "The damage-repair research programme is separated into an independent organization, SENS Research Foundation." }, { "year": "2009", "title": "SENS spun out", "text": "The damage-repair research programme is separated into an independent organization, SENS Research Foundation." }, { "year": "2014", "title": "New Organ", "text": "Prize competitions are extended to bioengineered organs and to organ preservation." }, { "year": "2014", "title": "New Organ", "text": "Prize competitions are extended to bioengineered organs and to organ preservation." }, { "year": "2021", "title": "Vascular Tissue Challenge awarded", "text": "A team from Wake Forest wins the NASA competition run in partnership with the foundation, producing thick vascularized tissue that survives for a month." } { "year": "2021", "title": "Vascular Tissue Challenge awarded", "text": "A team from Wake Forest wins the NASA competition run in partnership with the foundation, producing thick vascularized tissue that survives for a month." }lines 70–78 → 70–782 unchanged lines not shown
## Funding## Funding The foundation is philanthropically funded, and its most consequential single gift was from Peter Thiel in 2006 — several million dollars at a time when almost no private capital of that size was directed at aging. The gift mattered less for its amount than for its signalling effect on other technology donors, and much of the money that later founded [[calico]], [[altos-labs]] and [[retro-biosciences]] came from the same social network.The foundation is philanthropically funded, and its most consequential single gift was from Peter Thiel in 2006: a pledge of $3.5 million — $500,000 in direct funding for pilot SENS projects over three years, plus a 50-cent match for every donated dollar up to $3 million — at a time when almost no private capital of that size was directed at aging.[^fightaging2006] The pledge mattered less for its amount than for its signalling effect on other technology donors, and much of the money that later founded [[calico]], [[altos-labs]] and [[retro-biosciences]] came from the same social network. The organization later established the Methuselah Fund, a venture vehicle that invests in early-stage longevity and regenerative medicine companies, on the reasoning that some of the field's bottlenecks are commercial rather than scientific and that a nonprofit prize cannot address them.The organization later established the Methuselah Fund, a venture vehicle that invests in early-stage longevity and regenerative medicine companies, on the reasoning that some of the field's bottlenecks are commercial rather than scientific and that a nonprofit prize cannot address them. As of 2026 the foundation's own site presents its work as seven themed strategies — replacement parts, waste clearance, vascular restoration and the like — with the Fund as the investment vehicle and the Mprize described among its early awards.[^mfoundation2026] ## Reception## Reception lines 80–86 → 80–861 unchanged line not shown
The substantive criticism is about proportion. The sums involved are small — hundreds of thousands to low millions of dollars — relative to the cost of the work being incentivized, and the prizes have generally been won by researchers who were already doing the work rather than attracting new entrants. The Mprize's most-cited effect was reputational: it gave mouse longevity research a public scoreboard and made the field legible to donors.The substantive criticism is about proportion. The sums involved are small — hundreds of thousands to low millions of dollars — relative to the cost of the work being incentivized, and the prizes have generally been won by researchers who were already doing the work rather than attracting new entrants. The Mprize's most-cited effect was reputational: it gave mouse longevity research a public scoreboard and made the field legible to donors. A second criticism concerns the mission statement. "Make 90 the new 50 by 2030" is not a testable proposition, has no operational definition in terms of [[healthspan]] or function, and as of 2026 no route to meeting it on that timeline has been described. The foundation has continued to use it, which its critics read as the same rhetorical looseness that characterizes the [[longevity-escape-velocity]] literature more generally.A second criticism concerns the mission statement. "Make 90 the new 50 by 2030" is not a testable proposition, has no operational definition in terms of [[healthspan]] or function, and as of 2026 no route to meeting it on that timeline has been described. The foundation still states it as its overarching goal,[^mfoundation2026] which its critics read as the same rhetorical looseness that characterizes the [[longevity-escape-velocity]] literature more generally. ## Legacy## Legacy lines 104–107 → 104–11017 unchanged lines not shown
[^degrey2007]: `book` de Grey, A. and Rae, M. *Ending Aging: The Rejuvenation Breakthroughs That Could Reverse Human Aging in Our Lifetime*. St. Martin's Press, 2007. {A popular exposition of the author's own research agenda; it sets out a programme rather than reporting results.}[^degrey2007]: `book` de Grey, A. and Rae, M. *Ending Aging: The Rejuvenation Breakthroughs That Could Reverse Human Aging in Our Lifetime*. St. Martin's Press, 2007. {A popular exposition of the author's own research agenda; it sets out a programme rather than reporting results.}[^bartke2001]: `paper` Bartke, A. et al. "Extending the lifespan of long-lived mice." *Nature*, 2001. {The record rests on a germline dwarfing mutation present from birth, which is the case the prize's separate rejuvenation category was written to exclude.}[^bartke2001]: `paper` Bartke, A. et al. "Extending the lifespan of long-lived mice." *Nature*, 2001. {The record rests on a germline dwarfing mutation present from birth, which is the case the prize's separate rejuvenation category was written to exclude.}[^harrison2009]: `paper` Harrison, D.E. et al. "Rapamycin fed late in life extends lifespan in genetically heterogeneous mice." *Nature*, 2009. {Run at three independent sites on genetically heterogeneous mice, with dosing begun in late life; the gain is a percentage of median lifespan.}[^harrison2009]: `paper` Harrison, D.E. et al. "Rapamycin fed late in life extends lifespan in genetically heterogeneous mice." *Nature*, 2009. {Run at three independent sites on genetically heterogeneous mice, with dosing begun in late life; the gain is a percentage of median lifespan.}[^fightaging2006]: `news` "Peter Thiel Gives Us All a $6 Million Challenge." *Fight Aging!*, September 2006. {An advocacy blog reproducing the pledge's press-release terms — $500,000 over three years plus up to $3 million in matching funds through 2009; it records the commitment, not what was ultimately disbursed.}[^nasa2021]: `statement` NASA. "Vascular Tissue Challenge (2016–2021)." Centennial Challenges, nasa.gov. {NASA co-ran the competition it describes; the page records the challenge rules, the $500,000 purse, and the June 2021 award to two Wake Forest Institute for Regenerative Medicine teams.}[^mfoundation2026]: `statement` Methuselah Foundation. "What We Do." mfoundation.org, accessed August 2026. {The foundation's own description of its current strategies, mission statement and vehicles; it records what the organization says about itself, not an independent assessment.} removed, struck through added, underlinedLine numbers count the serialised markdown of each revision, frontmatter included.
99 lines are the same in both revisions, and 63 of them are not shown. Neither revision here is necessarily the current article — read Methuselah Foundation for the text this wiki stands behind today.